Therapeutic Efficacy of Risankizumab for Small-Intestinal Lesions in Crohn’s Disease: A Retrospective Study Using Double-Balloon Endoscopy
This study confirms the therapeutic efficacy of RZB for deep small-intestinal involvement in CD based on comprehensive DBE assessment. The results support the clinical utility of RZB in patients with refractory small-intestinal lesions, highlighting its potential to maintain 1 year disease control when ongoing mucosal inflammation is a concern. These findings underscore the importance of deep enteroscopic evaluation to optimize therapeutic strategies.
Authors
- Takashi Hirose (ORCID: https://orcid.org/0000-0002-3713-3072)
- Tsunaki Sawada (ORCID: https://orcid.org/0000-0002-4779-9708)
- Kentaro Murate
- Kazuhiro Furukawa (ORCID: https://orcid.org/0000-0001-5744-8306)
- Yasuyuki Mizutani (ORCID: https://orcid.org/0000-0002-4363-3161)
- Kentaro YAMAO
- Takeshi Yamamura
- Masanao Nakamura
- Tadashi Iida
- Yoji Ishizu
- Eri Ishikawa
- Hiroki Kawashima
- Takuya Ishikawa
- Takashi Honda
- Keiko Maeda
Institutions
- Nagoya University Hospital (JP)
- Nagoya University (JP)
Publication Details
- Journal
- Digestion
- Published
- 2026-02-09
- DOI
- https://doi.org/10.1159/000550396
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00